554 related articles for article (PubMed ID: 31796524)
1. Clinical and Economic Impact of Tailoring Screening to Predicted Colorectal Cancer Risk: A Decision Analytic Modeling Study.
Ladabaum U; Mannalithara A; Mitani A; Desai M
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):318-328. PubMed ID: 31796524
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
3. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
Sharaf RN; Ladabaum U
Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
[TBL] [Abstract][Full Text] [Related]
5. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score.
Sekiguchi M; Igarashi A; Sakamoto T; Saito Y; Esaki M; Matsuda T
J Gastroenterol Hepatol; 2020 Sep; 35(9):1555-1561. PubMed ID: 32167186
[TBL] [Abstract][Full Text] [Related]
9. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
[TBL] [Abstract][Full Text] [Related]
10. The economic evaluation of screening for colorectal cancer: Case of Iran.
Barouni M; Ghaderi H; Shahmoradi MK
Clin Lab; 2013; 59(5-6):667-74. PubMed ID: 23865368
[TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.
Gini A; Zauber AG; Cenin DR; Omidvari AH; Hempstead SE; Fink AK; Lowenfels AB; Lansdorp-Vogelaar I
Gastroenterology; 2018 Feb; 154(3):556-567.e18. PubMed ID: 29102616
[TBL] [Abstract][Full Text] [Related]
12. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
13. Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness.
van Hees F; Saini SD; Lansdorp-Vogelaar I; Vijan S; Meester RG; de Koning HJ; Zauber AG; van Ballegooijen M
Gastroenterology; 2015 Nov; 149(6):1425-37. PubMed ID: 26253304
[TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline.
Helsingen LM; Vandvik PO; Jodal HC; Agoritsas T; Lytvyn L; Anderson JC; Auer R; Murphy SB; Almadi MA; Corley DA; Quinlan C; Fuchs JM; McKinnon A; Qaseem A; Heen AF; Siemieniuk RAC; Kalager M; Usher-Smith JA; Lansdorp-Vogelaar I; Bretthauer M; Guyatt G
BMJ; 2019 Oct; 367():l5515. PubMed ID: 31578196
[TBL] [Abstract][Full Text] [Related]
15. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline.
Peterse EFP; Meester RGS; Siegel RL; Chen JC; Dwyer A; Ahnen DJ; Smith RA; Zauber AG; Lansdorp-Vogelaar I
Cancer; 2018 Jul; 124(14):2964-2973. PubMed ID: 29846933
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years.
Ladabaum U; Mannalithara A; Meester RGS; Gupta S; Schoen RE
Gastroenterology; 2019 Jul; 157(1):137-148. PubMed ID: 30930021
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy.
Ladabaum U; Mannalithara A; Weng Y; Schoen RE; Dominitz JA; Desai M; Lieberman D
Gastroenterology; 2024 Jul; 167(2):378-391. PubMed ID: 38552670
[TBL] [Abstract][Full Text] [Related]
18. The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis.
Thomas C; Mandrik O; Saunders CL; Thompson D; Whyte S; Griffin S; Usher-Smith JA
Cancer Prev Res (Phila); 2021 Aug; 14(8):811-822. PubMed ID: 34039685
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of colorectal cancer screening in high-risk Spanish patients: use of a validated model to inform public policy.
Ladabaum U; Ferrandez A; Lanas A
Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2765-76. PubMed ID: 20810603
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
